Treating Extensively Drug-Resistant Acinetobacter baumannii: Considerations for Host Characteristics and Type of...

Area of Science:

• * Infectious Diseases
• * Microbiology
• * Antimicrobial Resistance

Background:

• * Acinetobacter baumannii is a critical nosocomial pathogen, identified as an ESKAPE pathogen.
• * Infections caused by A. baumannii have a mortality rate exceeding 40%.
• * Carbapenem-resistant strains pose a significant public health threat.

Purpose of the Study:

• * To review the history, epidemiology, and evolution of resistance in Acinetobacter baumannii.
• * To highlight challenges in managing systemic infections caused by this pathogen.
• * To discuss available and pipeline antimicrobial treatments and their clinical evidence.

Main Methods:

• * Literature review of historical data, epidemiological studies, and resistance evolution.
• * Analysis of available antimicrobial agents and drugs in development.
• * Examination of clinical evidence on pharmacokinetics and efficacy.

Main Results:

• * Acinetobacter baumannii exhibits significant evolution of resistance, particularly to carbapenems.
• * Management of infections is complex, influenced by patient factors, infection site, and resistance profiles.
• * A comprehensive list of current and emerging antimicrobial treatments is provided.

Conclusions:

• * Effective management of Acinetobacter baumannii infections requires understanding its resistance patterns and epidemiological trends.
• * Treatment decisions must be individualized, considering patient-specific factors and antimicrobial susceptibility.
• * Further research and development of novel antimicrobials are crucial to combat this critical pathogen.